Bio-Techne (NASDAQ:TECH) Stock Unloaded Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Bio-Techne Co. NASDAQ: TECH. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Bio-Techne Stock Performance

Shares of TECH traded down $1.09 on Tuesday, reaching $52.81. 273,424 shares of the company's stock traded hands, compared to its average volume of 1,257,762. The stock's 50 day simple moving average is $54.51 and its two-hundred day simple moving average is $66.10. The stock has a market cap of $8.35 billion, a PE ratio of 53.37, a PEG ratio of 2.88 and a beta of 1.46. Bio-Techne Co. has a 52-week low of $46.01 and a 52-week high of $85.57. The company has a current ratio of 3.94, a quick ratio of 2.77 and a debt-to-equity ratio of 0.14.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.05. The firm had revenue of $316.18 million during the quarter, compared to analyst estimates of $317.92 million. Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. The business's revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted $0.48 EPS. On average, analysts forecast that Bio-Techne Co. will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 30th. Stockholders of record on Monday, May 19th will be paid a $0.08 dividend. The ex-dividend date of this dividend is Monday, May 19th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.61%. Bio-Techne's payout ratio is presently 39.02%.

Bio-Techne announced that its Board of Directors has approved a share buyback plan on Wednesday, May 7th that allows the company to buyback $500.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 6.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.

Analyst Upgrades and Downgrades

TECH has been the topic of several research reports. Robert W. Baird lowered shares of Bio-Techne from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $88.00 to $68.00 in a research report on Wednesday, February 19th. Stifel Nicolaus lowered their price target on shares of Bio-Techne from $75.00 to $60.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Citigroup dropped their price objective on Bio-Techne from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Baird R W downgraded Bio-Techne from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Finally, Scotiabank upped their price target on Bio-Techne from $88.00 to $90.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 6th. Seven investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $73.44.

Hedge Funds Weigh In On Bio-Techne

Institutional investors and hedge funds have recently made changes to their positions in the business. Sit Investment Associates Inc. boosted its position in Bio-Techne by 3.3% during the first quarter. Sit Investment Associates Inc. now owns 45,600 shares of the biotechnology company's stock valued at $2,674,000 after buying an additional 1,450 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Bio-Techne by 3.0% during the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 24,200 shares of the biotechnology company's stock worth $1,419,000 after acquiring an additional 700 shares during the last quarter. E Fund Management Co. Ltd. increased its stake in Bio-Techne by 13.4% in the 1st quarter. E Fund Management Co. Ltd. now owns 5,262 shares of the biotechnology company's stock worth $309,000 after purchasing an additional 621 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in Bio-Techne by 1,239.1% in the first quarter. Caitong International Asset Management Co. Ltd now owns 924 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 855 shares during the last quarter. Finally, S Bank Fund Management Ltd purchased a new stake in shares of Bio-Techne during the first quarter valued at approximately $103,000. Institutional investors own 98.95% of the company's stock.

Insider Transactions at Bio-Techne

In other Bio-Techne news, Director Amy E. Herr sold 1,860 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $65.96, for a total transaction of $122,685.60. Following the completion of the transaction, the director now owns 1,976 shares of the company's stock, valued at $130,336.96. This represents a 48.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.90% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.